CL2013002601A1 - Uso de 1-desoxigalactonojirimicina y una terapia de reemplazo de enzimas con alfa-gal a para tratar la enfermedad de fabry. - Google Patents
Uso de 1-desoxigalactonojirimicina y una terapia de reemplazo de enzimas con alfa-gal a para tratar la enfermedad de fabry.Info
- Publication number
- CL2013002601A1 CL2013002601A1 CL2013002601A CL2013002601A CL2013002601A1 CL 2013002601 A1 CL2013002601 A1 CL 2013002601A1 CL 2013002601 A CL2013002601 A CL 2013002601A CL 2013002601 A CL2013002601 A CL 2013002601A CL 2013002601 A1 CL2013002601 A1 CL 2013002601A1
- Authority
- CL
- Chile
- Prior art keywords
- deoxigalactonojirimycin
- gal
- alpha
- replacement therapy
- fabry disease
- Prior art date
Links
- 208000024720 Fabry Disease Diseases 0.000 title 1
- 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 title 1
- NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 title 1
- 238000002641 enzyme replacement therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01062—Glycosylceramidase (3.2.1.62)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451798P | 2011-03-11 | 2011-03-11 | |
| US201161578201P | 2011-12-20 | 2011-12-20 | |
| US201261596165P | 2012-02-07 | 2012-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002601A1 true CL2013002601A1 (es) | 2014-03-28 |
Family
ID=46831259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002601A CL2013002601A1 (es) | 2011-03-11 | 2013-09-10 | Uso de 1-desoxigalactonojirimicina y una terapia de reemplazo de enzimas con alfa-gal a para tratar la enfermedad de fabry. |
Country Status (16)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2787345T3 (pl) | 2006-05-16 | 2016-08-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry’ego |
| PL3470077T3 (pl) | 2008-02-12 | 2021-04-06 | Amicus Therapeutics, Inc. | Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| KR102330681B1 (ko) | 2013-03-11 | 2021-11-24 | 젠자임 코포레이션 | 당조작을 통한 부위-특이적 항체-약물 접합 |
| JP2017506520A (ja) * | 2014-02-17 | 2017-03-09 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 微生物学的方法 |
| EP4015535B1 (en) | 2014-03-19 | 2025-08-06 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| US9675627B2 (en) * | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| GB201508025D0 (en) * | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| EP3335126A4 (en) | 2015-08-11 | 2019-05-01 | Cognoa, Inc. | METHOD AND DEVICE FOR DETERMINING DEVELOPMENT PROGRESS WITH ARTIFICIAL INTELLIGENCE AND USER ENTRY |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| KR20190087673A (ko) * | 2016-03-22 | 2019-07-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| IL313907A (en) * | 2016-07-19 | 2024-08-01 | Amicus Therapeutics Inc | Treatment of Fabry disease in patients experienced with ERT-NAIVE and ERT |
| EP3539033B1 (en) | 2016-11-14 | 2024-10-02 | Cognoa, Inc. | Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability |
| CA3053245A1 (en) | 2017-02-09 | 2018-08-16 | Cognoa, Inc. | Platform and system for digital personalized medicine |
| PL4062916T3 (pl) * | 2017-05-30 | 2025-03-17 | Amicus Therapeutics, Inc. | Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje |
| US10251873B2 (en) | 2017-05-30 | 2019-04-09 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| JP7066157B2 (ja) | 2017-06-14 | 2022-05-13 | 学校法人 明治薬科大学 | ファブリー病治療用医薬の組合せ物及びその利用 |
| WO2019157047A1 (en) * | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| EP3840753B1 (en) * | 2018-08-20 | 2024-07-24 | Amicus Therapeutics, Inc. | Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene |
| MX2021011493A (es) | 2019-03-22 | 2022-01-04 | Cognoa Inc | Métodos y dispositivos de terapia digital personalizados. |
| EP3947458A1 (en) | 2019-04-03 | 2022-02-09 | Genzyme Corporation | Anti-alpha beta tcr binding polypeptides with reduced fragmentation |
| TW202112372A (zh) * | 2019-06-11 | 2021-04-01 | 美商阿米庫斯醫療股份有限公司 | 治療具有腎損害患者的Fabry氏病之方法 |
| TW202120087A (zh) | 2019-08-07 | 2021-06-01 | 美商阿米庫斯醫療股份有限公司 | 治療在GLA基因中具有突變的患者的Fabry氏病之方法 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| US20240197706A1 (en) * | 2022-12-13 | 2024-06-20 | Amicus Therapeutics, Inc. | Methods of improving the pharmacokinetics of migalastat |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551177A (en) * | 1984-04-23 | 1985-11-05 | National Starch And Chemical Corporation | Compressible starches as binders for tablets or capsules |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| JP5589165B2 (ja) * | 2003-01-31 | 2014-09-17 | マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー | タンパク質欠損性障害の治療のための併用療法 |
| US7879354B2 (en) * | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
| CN100457106C (zh) * | 2005-06-15 | 2009-02-04 | 同济大学 | 1-脱氧野尻霉素在制备治疗糖尿病肾病药物中的应用 |
| PL2787345T3 (pl) * | 2006-05-16 | 2016-08-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry’ego |
| AU2008232614A1 (en) * | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of Fabry disease using pharmacological chaperones |
| US9056101B2 (en) | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| US20100291060A1 (en) * | 2007-08-29 | 2010-11-18 | Shire Human Genetic Therapies, Inc | Subcutaneous administration of alpha-galactosidase a |
-
2012
- 2012-03-08 EA EA201301018A patent/EA031874B1/ru not_active IP Right Cessation
- 2012-03-08 SG SG2013067954A patent/SG193379A1/en unknown
- 2012-03-08 EP EP20160164.8A patent/EP3698792A1/en active Pending
- 2012-03-08 MX MX2013010446A patent/MX2013010446A/es unknown
- 2012-03-08 AU AU2012229330A patent/AU2012229330B2/en active Active
- 2012-03-08 KR KR1020137026394A patent/KR20140011367A/ko not_active Ceased
- 2012-03-08 EP EP12758017.3A patent/EP2683382B1/en active Active
- 2012-03-08 CN CN201280021877.8A patent/CN103974619B/zh active Active
- 2012-03-08 CA CA2829947A patent/CA2829947C/en active Active
- 2012-03-08 ES ES12758017T patent/ES2807502T3/es active Active
- 2012-03-08 SG SG10201604757RA patent/SG10201604757RA/en unknown
- 2012-03-08 WO PCT/US2012/028260 patent/WO2012125402A2/en active Application Filing
- 2012-03-08 US US14/004,335 patent/US20140219986A1/en not_active Abandoned
- 2012-03-08 JP JP2013557862A patent/JP2014528901A/ja active Pending
- 2012-03-08 CN CN201611235913.7A patent/CN107088225A/zh active Pending
- 2012-03-12 TW TW106126844A patent/TW201740945A/zh unknown
- 2012-03-12 TW TW101108345A patent/TWI624258B/zh not_active IP Right Cessation
- 2012-03-12 TW TW105118425A patent/TWI624259B/zh not_active IP Right Cessation
-
2013
- 2013-09-09 ZA ZA2013/06735A patent/ZA201306735B/en unknown
- 2013-09-10 CL CL2013002601A patent/CL2013002601A1/es unknown
-
2016
- 2016-06-28 AU AU2016204445A patent/AU2016204445B2/en active Active
-
2017
- 2017-03-01 JP JP2017038469A patent/JP2017132780A/ja active Pending
- 2017-10-12 US US15/782,431 patent/US20180153999A1/en not_active Abandoned
-
2018
- 2018-02-23 HK HK18102615.1A patent/HK1242998A1/zh unknown
- 2018-03-07 AU AU2018201637A patent/AU2018201637A1/en not_active Abandoned
-
2019
- 2019-10-10 JP JP2019186952A patent/JP2020033360A/ja active Pending
-
2020
- 2020-03-02 US US16/806,404 patent/US20200268890A1/en not_active Abandoned
- 2020-03-09 AU AU2020201715A patent/AU2020201715A1/en not_active Abandoned
-
2021
- 2021-02-08 JP JP2021018456A patent/JP2021098697A/ja not_active Withdrawn
-
2022
- 2022-05-05 AU AU2022203011A patent/AU2022203011A1/en not_active Abandoned
-
2023
- 2023-03-22 JP JP2023045001A patent/JP2023093448A/ja active Pending
- 2023-07-17 US US18/222,745 patent/US20240115708A1/en active Pending
-
2024
- 2024-07-31 AU AU2024205251A patent/AU2024205251A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013002601A1 (es) | Uso de 1-desoxigalactonojirimicina y una terapia de reemplazo de enzimas con alfa-gal a para tratar la enfermedad de fabry. | |
| HRP20160551T8 (hr) | Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora | |
| BR112013012969A2 (pt) | índices de fatiga e usos para os mesmos | |
| UY34782A (es) | Anticuerpos humanos para fel d1 y métodos para usarlos. | |
| BR112015001899A2 (pt) | interface de paciente e método para produzir a mesma. | |
| PT2590976E (pt) | Derivados da imidazopiridina, seu processo de preparação e sua utilização terapêutica | |
| CA145612S (en) | Patient interface assembly | |
| BR112013023737A2 (pt) | enzimas de glicosil hidrolase e utilização das mesmas para a hidrólise de biomassa | |
| BR112014006419A2 (pt) | métodos para tratar um paciente com câncer, kit e artigo | |
| BR112013018469A2 (pt) | dispositivos e métodos para tratamento de tecidos | |
| BR112014010658A2 (pt) | antígenos e vacinas direcionadas contra enterovírus humano | |
| CA145611S (en) | Patient interface assembly | |
| CO6970579A2 (es) | Sistema y método para tratar una actividad de excavación | |
| EP2405749A4 (en) | THERAPY TO LOW FREQUENCY GLATIRAMERATE ACETATE | |
| BR112014016292A2 (pt) | montagem de fixação occipito-cervical e método para construir a mesma | |
| BR112015031468A2 (pt) | corneta ultrassônica, soldador provido da mesma e método para produzir fralda descartável com o uso da corneta ultrassônica | |
| CO6821889A2 (es) | Compuestos de microarn y métodos para modular la actividad de mir-21 | |
| EP2734106A4 (en) | CONNECTOR FOR ELECTRODE ELECTRODE | |
| HRP20182175T1 (hr) | Pripravci za pomlađivanje kože | |
| PT3666827T (pt) | Géis de silicone secos e os seus métodos de produção | |
| IL232262A0 (en) | Therapeutic agents and uses thereof | |
| BR112013030356A2 (pt) | forro interno para pneu, método para produzir o mesmo, e pneu | |
| CO6870037A2 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| FI20115223A7 (fi) | Jousirakenne, resonaattori, resonaattorimatriisi ja anturi | |
| UY34186A (es) | ?procedimiento para revestir una superficie con micelas y superficie revestida con micelas?. |